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ABSTRACT
Acute pain is the hallmark of sickle cell disease and is the most common cause of hospital
admissions. Tissue damage due to vaso-occlusion releases numerous inflammatory mediators
that initiate the transmission of painful stimuli that culminate in the perception of pain. The acute
sickle cell painful crisis evolves along four phases. Each phase is coupled with changes in certain
markers of the disease. Hospital readmission occurs within 1 week in about 16% of discharged
patients and within 1 month in about 50% of discharged patients. Failure to treat acute pain
aggressively may lead to chronic pain syndrome which, in turn, initiates neuropathic pain.
Management of sickle pain is primarily pharmacological in nature and opioids are the analgesics
used most often. Adverse effects of opioids include histaminergic, excitatory, dopaminergic and
proserotonergic effects. Cellular and molecular mechanisms of opioids explain individual
differences among patients and justify the use of individualized treatment plans.
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INTRODUCTION
Sickle cell disease in general and sickle cell anemia (SS) in particular is a unique, paradoxical
and complex hematological disorder (1). On the one hand it is an inherited chronic disease and
yet, on the other hand, its most common and serious complication is recurrent attacks of acute
painful crises that often require treatment with parenteral opioids , especially in adults, in the
Emergency Room (ER) and/or the hospital (2). Some providers, especially non hematologists,
may be confused by this paradox of the disease and may consider chronic pain as the major
manifestation of this chronic disease that should be treated in the clinic or office with oral
analgesics. Moreover the complexity of this disease is due to the fact that it is a conglomerate of
at least four disorders encapsulated in one (2). These include: anemia and its sequelae, pain
syndromes, organ damage/failure and co-morbid conditions. Anemia is hemolytic in nature and
is often associated with cholelithiasis due to bilirubin stones. It may be exacerbated by aplasia
(3) or hyperhemolysis (4) and may require frequent blood transfusions leading to iron overload
(5). Moreover severe hemolysis may be associated with pulmonary hypertension, priapism and
leg ulcers (6). All organs may be adversely affected by sickle cell disease. The organs that are
most commonly affected include the spleen, the central nervous, pulmonary, hepatobiliary,
genitorenal, and musculoskeletal systems. This presentation will focus on pain syndromes and

their management as described below.
PAIN SYNDROMES
Sickle cell pain syndromes include an unusual triumvirate of acute, chronic and neuropathic pain
that occur sequentially or simultaneously with age as will be described below. Unlike other
diseases associated with chronic pain such as osteoarthritis, rheumatoid arthritis, fibromyalgia
and complex sympathetic dystrophy, sickle cell acute pain manifests itself in infancy and
continues to recur throughout the life span of the affected patient. With age acute pain retains its
unpredictable relapses and spawns chronic pain as a new partner in the rhapsody of pain and
suffering. Chronic pain may evolve into neuropathic pain. Acute pain, however, dominates the
clinical picture and requires urgent treatment with parenteral opioids in the ER and/or hospital.
The chronic pain syndromes due to the other disorders mentioned above rarely, if ever, require
management similar to that of acute sickle cell pain. They are usually treated as out patients with
oral analgesics. Nevertheless, they do encounter occasional negative attitudes and disparities
from some providers, albeit less frequent and less combative than what patients with sickle cell
disease encounter (7).
“Breakthrough” pain is another kind of pain often referred to by care providers following
patients with sickle cell disease. Literally this term means the act of breaking through pain relief.
Originally, this term was introduced by Coluzzi et al. (8) for patients with cancer pain and was
defined as a flair of sudden pain in patients with cancer pain that were maintained on a stable
dose of oral analgesics to achieve adequate relief. Such flair is usually sudden, and incidental,
precipitated by movement and lasts from a few seconds to a few hours. Recommended
management includes the administration of short-acting analgesics via a route that achieves
immediate relief such as parenteral or transmucosal. Details of the definition and management of
breakthrough pain are controversial to date and its application to other types of pain seems
unjustified. Health care providers treating patients with sickle cell pain use the term
“breakthrough” pain loosely for any pain that occurs in patients taking daily analgesics for
chronic pain and treat it with short-acting oral analgesics that are the same or different than the
long-acting analgesics the patients are already taking. Moreover, the short-acting analgesic is
often given several times a day in cumulative excessive doses that are as high as or even higher
than the daily dose of the long-acting opioids the patients are already taking. Thus, this kind of
practice is not for breakthrough pain but rather an administration of extra or rescue doses of
analgesics for pain that is inadequately treated in the first place and implies that the dose of the
long-acting analgesic used should be increased to achieve better pain relief.
PATHOPHYSIOLOGY OF SICKLE CELL PAIN
Acute Pain
Clinically acute sickle pain is typically sharp and/or throbbing in nature, of sudden or gradual
onset. It may last from minutes to weeks in duration. The average duration of an acute painful
crisis in adults, based on the length of hospital stay, is about 7 days (2,9). Acute sickle cell pain
is believed to be secondary to vaso-occlusion by sticky sickled erythrocytes that adhere to
vascular endothelium. Vascular occlusion leads to ischemia and consequent damage of the

tissues supplied by the occluded vessel. Tissue damage, in turn, creates a state of inflammation
with the release of several inflammatory mediators. The chemical energy created by
inflammation is transformed into an electrical impulse of pain transmitted along peripheral
nerves (Aδ (Author: please clarify this) and C fibers) to the dorsal horn of the spinal cord. The
impulse ascends along the contralateral spinothalamic tract to the thalamus which, in turn,
interconnects reversibly with the limbic system and other regions of the central nervous system
(CNS). At the same time the CNS tries to inhibit the transmission of the painful stimulus with
endogenous serotonin and epinephrine at the level of the dorsal horn via a genetically determined
descending pathway that starts in the periaqueductal gray matter of the midbrain. The modified
electrochemical pain impulse is eventually sent to the cerebral cortex where it is perceived as
pain. Thus, this sequence of events illustrates that pain is subjective in nature and is the end
result of a complex interplay among enhancing and inhibiting genetically determined factors at
the level of the CNS.
Each inflammatory mediator released peripherally after tissue damage binds to a specific
receptor on the neurons of peripheral nerves (10). These neurons are crowded with multiple
receptors for inflammatory mediators and for descending inhibitory pathways from the CNS.
This state of affairs of one neuron with multiple receptors implies that inhibition of the
transmission of the painful stimulus at the level of the peripheral nerve entails the blocking of all
these receptors. It is impossible to find one drug that blocks all these receptors. Blocking the
transmission of the painful stimulus peripherally requires the utilization of more than one
analgesic capable of blocking all or most of the neuronal receptors.
Chronic Pain
Clinically, chronic pain is simply pain that does not go away for 3 or more months. It is usually
described as pain that is deep, nagging and achy in nature that is there all the time. Chronic sickle
cell pain is of two types. The first is due to obvious objective signs including leg ulcers and
avascular necrosis. The second type is due to persistent or frequently recurrent acute painful
events. Recurrent attacks of acute severe painful crises, especially if not adequately treated, lead
to the creation of chronic pain syndrome. The pathophysiological events of this transformation
are not well understood. With the onset of chronic pain there seems to be a process of “rewiring” the brain where the threshold for pain perception is lowered so that ambient
environmental stimuli that are normally painless or mildly painful induce the perception of
severe pain. Hyperalgesia in this context is the perception of severe pain generated by stimuli
that are normally mildly painful and allodynia is the perception of severe pain by stimuli that are
normally painless (2,7,11,12).
Neuropathic Pain
Clinically, neuropathic pain is usually described as numb, tingling, lancinating, shooting or
paroxysmal in nature associated with a sensation of pins and needles. Its severity is also
enhanced by exposure to either cold or heat. This pain was believed to be secondary to nerve
injury whether peripherally or centrally. This definition has recently been modified by the
International Association for the Study of Pain (IASP) to include injury and dysfunction of
nerves as causes. Sickle cell neuropathic pain is also of two types. The first is due to obvious

objective signs due to tissue damage following vaso-occlusion of blood vessels of nerves (vasa
vasorum) such as mental nerve neuropathy and spinal cord infarction. The second seems to be
consequent to chronic pain. To that end, persistent chronic pain and/or its management seem to
cause the perception of neuropathic pain. The pathophysiological events leading to this
transformation are also not well understood. Activation of the glia seems to be the root cause of
neuropathic pain. The mechanisms of glial activation are beyond the scope of this presentation
and are available in the listed references (2,7,11,12).
Management of Sickle Cell Pain
Effective management of sickle cell pain is complex and entails a thorough understanding of the
issues that are associated with the treatment of pain in an incurable chronic disease (1-4). Major
prerequisites for an effective and rational management of sickle cell pain pertain to the patient,
the pathophysiology of the disease, the pharmacology of analgesics, and the attitude of the health
care providers. A patient is a unique human entity. The more a provider knows the patient, the
more effective pain management becomes. Knowledge of the patient should not be limited to
age, sex, precise diagnosis, complications and previous pain management methods. It should also
take into consideration the biopsychosocial fabric of the patients’ lives, including their level of
education, employment status, occupation, family structure, source of income, ethnicity, housing
conditions, fears, religion, beliefs, habits, hobbies, and perception of the severity and prognosis
of their disease. This approach allows the physician to individualize pain management and avoid
unfounded generalizations about patients and their consumption of opioid analgesics. Such
generalizations, for instance, may result in over sedation of a patient naive to opioids or in under
treatment of a patient tolerant to them.
Non Pharmacologic Management of Pain
Nonpharmacologic management of pain includes the use of heat or cold packs, distraction,
relaxation, massage, music, guided imagery, self-hypnosis, self-motivation, and acupuncture.
Although there are no controlled clinical trials of the efficacy of these methods in the
management of sickle cell pain, there are many anecdotal reports of their efficacy in pain
management, both by patients and providers (2). These approaches may increase the level of
endogenous endorphins that are known to have analgesic effects similar to those of exogenous
opioids but without the side effects associated with opioids (11,12).
Pharmacologic Management of Pain
Pharmacologic management of sickle cell pain includes three major classes of compounds: non
opioids, opioids, and adjuvants (12,13,(?)63(?)). Non opioids include acetaminophen, non
steroidal anti-inflammatory drugs (NSAIDs), topical agents and corticosteroids. Most commonly
used opioid analgesics include the mu-agonists, although the mixed agonist/antagonist
buprenorphine and the partial agonist pentazocine have achieved some popularity, especially in
Europe. Adjuvants commonly used in the management of sickle cell pain include antihistamines,
benzodiazepines, antidepressants, anticonvulsants and phenothiazines. The short-acting opioids
are usually used to treat acute pain whereas controlled-release opioids and long-acting opioids
are used in the management of chronic pain.

Pain Management of Out Patients
Management of patients with sickle cell disease as out patients in the clinic or office is extremely
important and is the basis on which future treatments and interventions are based. Patients should
be followed by the same providers in order to maintain continuity of care. The most important
aspect of out patient management is the collection of steady state data that include detailed
medical history, physical examination, known complications, medications, and comprehensive
laboratory data. Management of exacerbations in the ER or in the hospital depends heavily on
knowing the steady state parameters of the patient in question. It is highly desirable that patients
be seen and evaluated in the office or clinic by a social worker and a psychologist or psychiatrist.
It is in the out patient set up, that details of care in general and in the ER, day unit, and hospital
are explained and discussed. The pros and cons of all medications the patient is taking will be
reviewed. Prescriptions will be given as needed. Vaccines will be administered when required
(2,13-16).
In the out patient setting, patients should be empowered to cope with their disease and be
authorities on its manifestations that apply to them individuality. This includes education about
sickle cell disease, its genetic basis, inheritance and family counseling; adherence to regular
schedule of medical follow-up; avoidance of situations that exert an adverse effect on their
disease and adoption of those activities of daily living that are beneficial to them; knowing their
rights and responsibilities as patients with sickle cell disease when dealing with care providers,
medical facilities and the workplace; and participation in local support groups and
communication with community leaders and advocates.
Management and follow-up of outpatients in the office and clinic should culminate in an
individualized treatment plan for each patient. Such a plan should summarize pertinent aspects of
the medical history, physical examination, laboratory data, complications and treatment plans as
out patients, in the day unit, ER and the hospital. In some places, the treatment plan may be
transformed into an ID card to be carried by the patient and presented to care provider as needed
(17).
Pain Management in the Emergency Room
Treatment of acute sickle cell painful episodes in the ER follow similar principles of thorough
assessment, treatment with analgesics/adjuvants, coordination of care, monitoring, outcome and
disposition. The major problem in the ER is the length of waiting time to initial analgesia which
could be up to several hours. Needless to say, that waiting while in pain constitutes a stressful
situation that could worsen the painful crises and render it no longer amenable to resolution and
discharge from the ER but to hospital admission. Many ERs are in the process of determining
and implementing strategies that could shorten the time to initial treatment (2,13-15).
Specific treatment in the ER should be based on the history or the computerized version of the
treatment plan if available. Usually analgesics are given individually every 2 hours for a total of
three doses. Adjuvants may also be given intravenously or orally as needed. If the pain is
resolved or reduced to a level with which the patient is comfortable, the patient is discharged

with instructions for follow-up by the primary care physician (PCP) and/or hematologist.
Otherwise the patient will be admitted to the hospital.
Management of Sickle Cell Pain in the Hospital
Successful management of the acute painful crisis in the hospital should include the following
steps (2,13,14,18): (1) Multidimensional assessment to determine the location of pain, its
intensity, its quality, precipitating factors, modifying factors, triggers, and to determine mood,
pain relief and sedation in addition to checking the vital signs including pulse oximetry. (2)
Choice of analgesics (opioids/non opioids), adjuvants, and hydration if needed; such choices are
individualized based upon the past medical history and the assessment of the patient in question.
If the acute painful episode is superimposed on chronic pain for which the patient is taking longacting/controlled-release opioids with short-acting opioids for rescue doses in between, keep the
long-acting/controlled-release opioids the same and discontinue the short-acting ones. (3)
Determination of the route and method of administration of analgesics. These, again, should be
individualized; parenteral analgesics are usually administered either on a fixed schedule or via a
Patient controlled analgesia (PCA) pump. (4) Titration of the dose of analgesics to achieve relief
with which the patient is comfortable. (5) Maintenance of the dose that achieves adequate relief.
Consider opioid rotation, i.e., change the opioid chosen initially to an equianalgesic other opioid
if its usage does not achieve or maintain relief. (6) Plan to treat neuropathic pain if present, and
side effects of the crisis or the analgesics, if present. (7) Tapering the dose of analgesics once the
patient uses the PCA pump less frequently or the intensity of pain decreases by two or more
points. (8) Gradual switching to oral analgesics using tables of equianalgesic doses as an initial
guide. One example would be to decrease the parenteral dose by 25% and replace it with an
equianalgesic oral dose. The latter should be adjusted according to its effect to achieve pain relief
with which the patient is comfortable. (9) Prevention of withdrawal by using either clonidine
patch or methadone. (10) Plan for discharge and follow-up.
Opioid Treatment Guidelines
Management of outpatients with pain using oral opioids should follow the recently published
recommendations established by the American Pain Society and the American Academy of Pain
Medicine (19). These recommendations emphasize minimizing the risks associated with
prescribing opioids within the framework of optimizing analgesia to achieve adequate pain relief
for patients using opioids on a regular and chronic basis.
Optimize Analgesia
Management of patients with sickle cell pain with chronic opioids can be effective if the drug is
carefully selected and if the patients with sickle cell pain are monitored despite limited evidence
in the literature. Failure to optimize analgesia may cause seemingly aberrant behavior such as
pseudo-addiction (20) or serious maladaptive behavior such as the use of illicit street drugs in
order to achieve adequate pain relief (21).
Minimize Risk
It is well known that opioids are associated with serious side effects and outcomes related to

abuse, misuse and diversion of prescribed opioids. To that end, providers should follow the
recommended guidelines to minimize the risks associated with opioids. Recommended
procedures to minimize the risk of abuse, misuse and diversion include the following (20): (1)
Obtain detailed history and physical exam on every patient enrolled in your practice. (2)
Document all subsequent encounters with the patient including progress notes, vital signs,
laboratory data, changes in physical examination if any, changes in clinical picture if any,
prescriptions written, etc. (3) Establish a consent (or agreement) form and individualized
treatment plan for every patient and revise periodically as needed. (4) Prescribe opioids for 1
month at a time. (5) Establish refill policy for every patient. For example: prescription refills
without seeing the patient will be approved on two consecutive occasions only. Additional refills
will not be approved until the patient is seen, examined and evaluated by the provider. (6) Do pill
and patch count whenever the patient is seen in person. (7) Non compliance or breach of the
agreement form and treatment plan must trigger counseling and discussions with the patient to
emphasize the seriousness of these deviations and to revise the plans if needed. (8) Do random
urine drug testing using zero cutoffs for opioids. (9) Learn how to interpret the results of the
screening test for urine drugs and/or seek help in their interpretation. Perform confirmatory
testing if needed. (10) Document, document and document all details in the patient’s file.
CONCLUSIONS
Pain is the hallmark of sickle cell disease and the most frequent reason for hospital admissions.
Pain sensation results from a very complex and interactive series of mechanisms integrated at all
levels of the nervous system: from the peripheral nerve fibers, via the dorsal root ganglion and
via the dorsal horn of the spinal cord, the thalamus and the limbic system to the higher cerebral
cortex where pain is perceived. Recently, there have been major advances in understanding the
pathophysiologic mechanisms of pain sensation and its complications as well as newer
approaches that impact the assessment and management of patients with sickle cell pain.
Progress in this area may minimize the pain and suffering of patients with sickle cell disease and
improve their quality of life.
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